LGALS3 and rheumatoid arthritis: In conclusion, circulating galectin-3 concentrations are associated with the clinical outcomes in patients with CVD and RA.47,70–72 This study identifies CIA as a model to assess the clinical utility of galectin-3 determination for CVD prediction in patients with RA.